Loading...
Market
Zepbound's impact on health measures in sleep apnea patients by end of 2024?
3
Resolution / Starting Odds
Improves blood pressure only • 33%
Improves blood pressure and one other measure • 33%
Improves blood pressure and multiple other measures • 33%
Clinical trial results and medical studies
Story
Eli Lilly's Zepbound Weight Loss Drug Shows Promise in Treating Sleep Apnea
Jun 22, 2024, 10:54 PM
A new study has found that a popular weight loss drug may also help treat sleep apnea, a condition where individuals struggle to breathe while sleeping. The drug, which is commonly used for obesity, showed potential in reducing the severity of sleep apnea. This discovery was highlighted at the American Diabetes Association's 84th Annual Scientific Sessions. The study's findings suggest that the drug could offer a dual benefit for patients dealing with both obesity and sleep apnea. Additionally, the drug's ability to improve blood pressure and other health measures was noted, further enhancing its therapeutic profile. Eli Lilly's Zepbound helped resolve obstructive sleep apnea in 43-51.5% of patients.
View original story
Similar markets
Cost decreases significantly • 25%
Cost decreases slightly • 25%
Cost remains the same • 25%
Cost increases • 25%
Less than 60% • 25%
60% to 70% • 25%
70% to 80% • 25%
More than 80% • 25%
≥ 50% • 50%
< 50% • 50%
≥ 40% • 25%
30-39% • 25%
20-29% • 25%
< 20% • 25%
Yes • 50%
No • 50%
Less than 100,000 • 25%
100,000 to 200,000 • 25%
200,001 to 300,000 • 25%
More than 300,000 • 25%
≥ 40% • 50%
< 40% • 50%